Stock Movers
Stock Movers

Jul 16, 2026 · 6 min

Abbott Laboratories raises guidance as JB Hunt and GH Research climb

JB Hunt Gains, GH Research Rises, Abbott Laboratories Surges on 2026 Profit Guidance Raise

Corporate guidance adjustments from industry leaders offer critical signals about the resilience of consumer demand and healthcare spending.

3 key takeaways
  1. 1Abbott Laboratories boosted its 2026 profit guidance, signaling robust long-term growth in its medical portfolios.
  2. 2JB Hunt shares gained ground as transport sector investors reacted to the latest logistical demand signals.
  3. 3GH Research saw its stock rise, reflecting renewed investor interest in clinical-stage biotechnology pipelines.

The brief

Corporate earnings forecasts are shifting market dynamics as major players across transport, healthcare, and biotechnology report critical updates to their financial outlooks.

Abbott Laboratories is drawing intense investor focus after raising its 2026 profit guidance, signaling long-term confidence in its core healthcare and medical device portfolios.

At the same time, transport giant JB Hunt and clinical-stage biotechnology firm GH Research are seeing notable market gains, highlighting a broader risk-on appetite for diverse sectors.

What was said on this episode

7 statements · 6 positive · 1 negative

  1. Matthew Griffinon Abbott LaboratoriesPositive1:02

    Abbott Laboratories raised full-year adjusted profit guidance to $5.45–$5.60 per share.

    “that stock ticker ABT having its best day in 24 years, up as much as 14% after the MedTech company beat expectations in the most recent quarter. They raised guidance for the full year. They now see their profit at $5.45 to $5.60 excluding some items.”

    Listen at 1:02

  2. Matthew Griffinon Abbott LaboratoriesPositive1:47

    Abbott Laboratories is relatively insulated from expiring Obamacare subsidies.

    “Ford said Abbott's relatively insulated there. They get a lot of their surgical procedures covered under Medicare.”

    Listen at 1:47

  3. “J.B. hunt having a good day. They're up 5.4%. The transportation company beat expectations also in the most recent quarter. Their profit was A$91 per share. Analysts looking for A$74 cents.”

    Listen at 2:04

  4. Matthew Griffinon US trucking market improvementPositive2:19

    Improvement in the US trucking market is increasing revenue for major transportation companies.

    “this is the latest sign that improvement in the US trucking market is flowing through into revenue into for the biggest companies in the sector.”

    Listen at 2:19

  5. Matthew Griffinon Rising trucking ratesPositive2:29

    Rising trucking rates are benefiting transportation companies.

    “Trucking rates had been rising. But we were really waiting for this earnings season to confirm that it would benefit the companies. So far, so good.”

    Listen at 2:29

  6. J.B. Hunt’s further upside could be difficult because much is already priced in.

    “Morgan Stanley does say a lot's priced in here now, so upside could be hard to find.”

    Listen at 2:51

  7. GH Research is among the main beneficiaries of large drugmakers’ psychedelic-therapy interest.

    “Investors are taking that as a sign that large drug makers are interested in psychedelic therapies. They're one of the main beneficiaries.”

    Listen at 3:49

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.